BioSight: Biosight Reports Final Primary Endpoint Data from Phase 2b Study of Aspacytarabine (BST-236) for First-Line Acute Myeloid Leukemia Therapy

(marketscreener.com) Complete remission rate of 37%, of which 50% were minimal residual disease negative Single-agent activity and favorable safety demonstrated in most challenging AML patient populations Study results presented at the 2021 ASH Annual Meeting AIRPORT CITY, Israel, Jan. 06, 2022 -- Biosight Ltd., a pharmaceutical development company...https://www.marketscreener.com/news/latest/Biosight-Reports-Final-Primary-Endpoint-Data-from-Phase-2b-Study-of-Aspacytarabine-BST-236-for-Fir--37484802/?utm_medium=RSS&utm_content=20220106